ClinicalTrials.gg

Program

brepocitinib

Also written as “PF-06700841”, “Brepocitinib” and “Oral Brepocitinib”.

Its studies are mostly in Psoriasis · Dermatomyositis · Sarcoidosis · Lichen Planus · Uveitis, led by 2 companies.

Furthest: phase 3, since Nov 4, 201625 company-led studies, 2 open or runningNext primary completion: Dec 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer200 open or runningphase 2since Nov 4, 2016Nov 18, 2014none ahead
Priovant Therapeutics52 open or runningphase 3since Jun 24, 2022Jun 24, 2022Dec 31, 2028phase 3 · NCT06978725

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Nov 18, 2014.

  1. Dec 6, 2018Phase 1 study in Healthy Male SubjectsPfizer · NCT03770039 · 6 enrolled · Netherlands
  2. Feb 15, 20192 phase 2 studiesPfizer · NCT03845517, NCT03850483
  3. Mar 20, 2019Phase 1 study in HealthyPfizer · NCT03916250 · 20 enrolled · Japan
  4. Mar 20, 2019Phase 2 study in Dermatitis, AtopicPfizer · NCT03903822 · 292 enrolled · United States, Australia, Bulgaria and more
  5. May 15, 2019Phase 2 study in Arthritis, PsoriaticPfizer · NCT03963401 · 219 enrolled · Australia, Bulgaria, Czechia and more
  6. Sep 12, 2019Phase 1 study in Heathy ParticipantsPfizer · NCT04090047 · 12 enrolled · United States
  7. Sep 15, 2019Phase 2 study in Hidradenitis SuppurativaPfizer · NCT04092452 · 194 enrolled · United States, Australia, Canada
  8. Feb 5, 20202 phase 1 studiesPfizer · NCT04260464, NCT04267250
  9. Sep 25, 2020Phase 1 study in Healthy ParticipantsPfizer · NCT04580797 · 36 enrolled · United States
  10. Jun 24, 2022Priovant Therapeutics's first study: phase 3 study in DermatomyositisNew to Priovant TherapeuticsPriovant Therapeutics · NCT05437263 · 241 enrolled · United States, Argentina, Belgium and more
  11. Aug 25, 2022Phase 2 study in UveitisPriovant Therapeutics · NCT05523765 · 26 enrolled · United States
  12. May 23, 2024Phase 2 study in DermatomyositisPriovant Therapeutics · NCT06433999 · 5 enrolled · United States
  13. Apr 30, 2025Phase 3 study in SarcoidosisPriovant Therapeutics · NCT06978725 · 168 planned · United States, Australia, United Kingdom
  14. Apr 3, 2026Phase 3 study in Lichen PlanusPriovant Therapeutics · NCT07532603 · 342 planned · United States, Australia, Canada and more

Ahead

  1. Dec 31, 2028Primary completion: phase 3 study in Lichen PlanusPriovant Therapeutics · NCT07532603
  2. Dec 31, 2028Primary completion: phase 3 study in SarcoidosisPriovant Therapeutics · NCT06978725

TargetBeta

JAK1 →TYK2 →read by rule
“An orally available, selective inhibitor of non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2) and tyrosine-protein kinase JAK1 (Janus kinase 1; JAK1) ”NCIt, by rule
“Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK1 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
delgocitinibruleLEO Pharmaphase 321
FXS5626Fosun Pharmaphase 33

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07532603Lichen Planus · United States, Australia, Canada and more3RecruitingPriovant TherapeuticsDec 31, 2028342
NCT06978725Sarcoidosis · United States, Australia, United Kingdom3RecruitingPriovant TherapeuticsDec 31, 2028168
NCT06433999Dermatomyositis · United States2CompletedPriovant TherapeuticsFeb 28, 20255
NCT05523765Uveitis · United States2CompletedPriovant TherapeuticsJul 30, 202426
NCT05437263Dermatomyositis · United States, Argentina, Belgium and more3CompletedPriovant TherapeuticsJul 17, 2025241
NCT04580797Healthy Participants · United States1CompletedPfizerJan 11, 202136
NCT04267250Healthy Female Volunteers · United States1CompletedPfizerNov 6, 202018
NCT04260464Renal Insufficiency · United States1CompletedPfizerMay 4, 202230
NCT04092452Hidradenitis Suppurativa · United States, Australia, Canada2CompletedPfizerJan 10, 2022194
NCT04090047Heathy Participants · United States1CompletedPfizerDec 19, 201912
NCT03963401Arthritis, Psoriatic · Australia, Bulgaria, Czechia and more2CompletedPfizerApr 6, 2020219
NCT03916250Healthy · Japan1CompletedPfizerApr 15, 201920
NCT03903822Dermatitis, Atopic · United States, Australia, Bulgaria and more2CompletedPfizerMay 7, 2020292
NCT03850483Psoriasis · United States, Australia, Bulgaria and more2CompletedPfizerApr 20, 2021344
NCT03845517Lupus Erythematosus, Systemic · United States, Argentina, Australia and more2CompletedPfizerOct 5, 2023350
NCT03770039Healthy Male Subjects · Netherlands1CompletedPfizerFeb 21, 20196
NCT03765554Healthy Participants · Belgium1CompletedPfizerApr 3, 20198
NCT03715829Active Non-segmental Vitiligo · United States, Australia, Belgium and more2CompletedPfizerFeb 5, 2021366
NCT03656952Healthy · Belgium1CompletedPfizerFeb 6, 201933
NCT03395184Crohn Disease · United States, Australia, Austria and more2CompletedPfizerOct 19, 2023244
NCT03236493Healthy · Belgium1CompletedPfizerSep 17, 20178
NCT02974868Alopecia Areata · United States, Australia, Canada2CompletedPfizerMay 15, 2019142
NCT02969018Chronic Plaque Psoriasis · United States, Canada, Poland2CompletedPfizerMar 2018212
NCT02958865Colitis, Ulcerative · United States, Austria, Bulgaria and more2CompletedPfizerMay 10, 2021319
NCT02310750Plaque Psoriasis · United States1CompletedPfizerJan 201696

How it is read

Names in the registry

  • “PF-06700841”, 13 entries
  • “Brepocitinib”, 3 entries
  • “Oral Brepocitinib”, 2 entries
  • “PF-06700841 15 mg”, 1 entry
  • “PF-06700841 30 mg”, 1 entry

Codes read as this program: PF06700841.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.